Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
This study is ongoing, but not recruiting participants.
Study NCT00831467   Information provided by CureVac GmbH
First Received: January 27, 2009   Last Updated: January 11, 2012   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2012
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
No publications provided by CureVac GmbH

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojki?-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011 Jan;34(1):1-15.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services